1. Search Result
Search Result
Results for "

CD276

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

6

Inhibitory Antibodies

17

Recombinant Proteins

7

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99740

    CD276/B7-H3 ADC Antibody Cancer
    Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .
    Mirzotamab
  • HY-P99157

    CD276/B7-H3 Cancer
    Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
    Omburtamab
  • HY-P990279

    CD276/B7-H3 Apoptosis STAT Inflammation/Immunology Cancer
    Anti-Mouse CD276/B7-H3 Antibody (MJ18) is a rat-derived anti-mouse CD276/B7-H3 IgG1 monoclonal antibody. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can inhibit CD276/B7-H3 and induce tumor cell apoptosis. Anti-Mouse CD276/B7-H3 Antibody (MJ18) enhances anti-tumor immune response by reducing immunosuppressive cells and promoting T cell activation. Anti-Mouse CD276/B7-H3 Antibody (MJ18) can be used for research on cancer such as breast cancer and prostate cancer .
    Anti-Mouse CD276/B7-H3 Antibody (MJ18)
  • HY-145636

    AEX4089DC1; MGC018

    Antibody-Drug Conjugates (ADCs) Cancer
    Vobramitamab duocarmazine (AEX4089DC1; MGC018), a humanized antibody-drug conjugate (ADC) targeted against B7-H3 (CD276). Vobramitamab duocarmazine is comprised of the cleavable linker-Duocarmycin payload, Vc-seco-DUBA (HY-128957), conjugated to an anti-B7-H3 humanized IgG1κ monoclonal antibody. Vobramitamab duocarmazine has antineoplastic activity .
    Vobramitamab duocarmazine
  • HY-RS17006

    Small Interfering RNA (siRNA) Others

    Cd276 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cd276 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd276 Mouse Pre-designed siRNA Set A
    Cd276 Mouse Pre-designed siRNA Set A
  • HY-RS02220

    Small Interfering RNA (siRNA) Others

    CD276 Human Pre-designed siRNA Set A contains three designed siRNAs for CD276 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CD276 Human Pre-designed siRNA Set A
    CD276 Human Pre-designed siRNA Set A
  • HY-RS23449

    Small Interfering RNA (siRNA) Others

    Cd276 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cd276 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cd276 Rat Pre-designed siRNA Set A
    Cd276 Rat Pre-designed siRNA Set A
  • HY-P990340

    CD276/B7-H3 Inflammation/Immunology
    Anti-B7-H3/CD276 Antibody is a CHO-expressed human antibody targeting B7-H3/CD276. Anti-B7-H3/CD276 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-B7-H3/CD276 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-B7-H3/CD276 Antibody
  • HY-P992110

    DB-1311 Antibody; BNT324 Antibody

    CD276/B7-H3 Cancer
    Elfetabart is a humanized monoclonal antibody targeting CD276 with antitumor activity. The antibody isotype of Elfetabart is human IgG1κ, and the recommended isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Elfetabart
  • HY-P992158

    CD47 Cancer
    VBI-009 is a CD47 and B7-H3 (CD276) bispecific antibody. VBI-009 blocks CD47-SIRPα 'don't eat me' signals and restricts activity to CD47 +/B7-H3 + cells. VBI-009 induces antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) in CD47 +/B7-H3 + tumor cells. VBI-009 inhibits tumor growth in CD47+/B7-H3+ lung cancer xenograft models. VBI-009 can be used for the research of lung cancer .
    VBI-009

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: